newsfilter
← Latest News
GlobeNewswire·

Eikon Therapeutics to Participate in Multiple Investor Conferences in November

  • Eikon Therapeutics CEO Roger M. Perlmutter will present at the JP Morgan Biotech Call series in Boston on November 6, 2026, at 2:00 pm EST.
  • CEO Roger M. Perlmutter will also participate in a fireside chat at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026, at 8:00 pm EST.
  • CMO Roy Baynes will join a Morgan Stanley Biotech Webcast in New York City on November 3, 2026, at 10:30 am EST to discuss new data & the synthetic lethality landscape.
  • Live audio/video webcasts for these events will be accessible via investors.eikontx.com, with archived versions available for approximately 30 days post-event.
  • Eikon is a late-stage clinical biopharmaceutical company focused on oncology, utilizing a proprietary single molecule tracking system to develop novel therapies.
  • The press release includes standard forward-looking statements regarding therapeutic potential, development timelines, & financial performance, accompanied by associated risk factors.